The latest biotech news

News and Trends 29 Nov 2022

Biocomposites antibiotic carrier, STIMULAN, receives approval for use in Mexico

UK-based medical devices company, Biocomposites Ltd., has announced that antibiotic carrier STIMULAN has received a new broad-based approval for use in bone and soft tissue in Mexico. The approval, granted by COFEPRIS, the Mexican Regulatory Authority, authorizes the use of STIMULAN as a carrier of substances such as antibiotics that are chosen by the surgeon […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

Mycotechnology and IFF join forces in Europe to create better food system

Mycotechnology, a company using mycelia, the roots of mushrooms, and IFF have formed a partnership to co-develop alternative proteins. The two companies have already partnered in the U.S. and the new collaboration in Europe, they say, reflects their shared commitment of bringing a better food system and ‘next-generation’ food and drink products to the European […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Molecure to conduct cancer treatment trial in Poland

Molecure S.A. says the President of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has given the company permission to conduct the first clinical trial of OATD-02. The planned phase I trial will be an open-label, multi-center, dose escalation study to evaluate safety, tolerability, anti-cancer activity and to establish the […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Replay receives $1.5M grant for hypoimmunogenic technology platform

Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Localizing BRCA gene mutations to better treat ovarian cancer

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […]

November 28, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Biomemory raises €5M to advance DNA digital data storage solution

Biomemory, a start-up focused on DNA data synthesis and storage, has closed a €5 million ($5.2 million) seed investment for the development of its technology. The seed funding round was led by eureKARE and the French Tech Seed Fund, managed on behalf of the French State by Bpifrance within the scope of France 2030, with […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Aptamer opens new facilities to meet growing demand for Optimer technology

Aptamer Group developer of Optimer binders that enable development in the life sciences industry has opened new facilities in the UK’s York Science Park. It says this will enable it to meet the growing demand for Optimer technology. Well-known and respected neuroscience researcher, Baroness Susan Greenfield, opened the new 18,000 square-foot site on November 25. […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

November 28, 2022 - 3 minutesmins - By Liza Laws

More News! 28 Nov 2022

Monkeypox stigma and racism set to end by renaming to mpox, WHO reports

The World Health Organisation (WHO) said today (November 28) it will begin using mpox, as a synonym for monkeypox. The organization confirmed that both names will be used simultaneously for a year while monkeypox is phased out. This is because of stigmatizing language and monkeypox racism that was appearing online. Some communities observed and reported […]

November 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

STORM Therapeutics doses first patient with drug targeting solid tumors

STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […]

November 28, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Biocomposites antibiotic carrier, STIMULAN, receives approval for use in Mexico

Mycotechnology and IFF join forces in Europe to create better food system

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

Molecure to conduct cancer treatment trial in Poland

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Replay receives $1.5M grant for hypoimmunogenic technology platform

Localizing BRCA gene mutations to better treat ovarian cancer

Biomemory raises €5M to advance DNA digital data storage solution

Aptamer opens new facilities to meet growing demand for Optimer technology

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Monkeypox stigma and racism set to end by renaming to mpox, WHO reports

STORM Therapeutics doses first patient with drug targeting solid tumors

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!